{
    "pmcid": "10154539",
    "qa_pairs": {
        "What genetic origin does XG005 share with other potent antibodies like LY-CoV1404?": [
            "IGHV2-5/IGLV2-14",
            "IGHV3-53/IGLV3-21",
            "IGHV1-69/IGLV1-40",
            "IGHV4-34/IGLV4-69"
        ],
        "What is the primary target for neutralizing antibodies in SARS-CoV-2, as discussed in the paper?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein",
            "The membrane protein",
            "The envelope protein"
        ],
        "What strategy does the paper suggest for designing nanobodies with broad neutralization capabilities?": [
            "Targeting conserved regions of the spike protein",
            "Focusing on the variable regions of the spike protein",
            "Enhancing glycosylation sites on the spike protein",
            "Increasing the hydrophobicity of the nanobodies"
        ],
        "What structural technique was used to reveal how XG005 interacts with the RBD of the spike protein?": [
            "Cryo-electron microscopy (cryo-EM)",
            "X-ray crystallography",
            "Nuclear magnetic resonance (NMR) spectroscopy",
            "Atomic force microscopy (AFM)"
        ],
        "Which antibody identified in the study retains potent neutralizing activity against all known SARS-CoV-2 variants of concern, including Omicron sublineages?": [
            "XG005",
            "LY-CoV1404",
            "Bamlanivimab",
            "Casirivimab"
        ]
    }
}